CN116178297A - Drimane type sesquiterpene heterocyclic compound and preparation method and application thereof - Google Patents

Drimane type sesquiterpene heterocyclic compound and preparation method and application thereof Download PDF

Info

Publication number
CN116178297A
CN116178297A CN202310070493.5A CN202310070493A CN116178297A CN 116178297 A CN116178297 A CN 116178297A CN 202310070493 A CN202310070493 A CN 202310070493A CN 116178297 A CN116178297 A CN 116178297A
Authority
CN
China
Prior art keywords
formula
structure shown
reaction
compound
temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202310070493.5A
Other languages
Chinese (zh)
Other versions
CN116178297B (en
Inventor
李圣坤
胡女丹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guizhou University
Original Assignee
Guizhou University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guizhou University filed Critical Guizhou University
Priority to CN202310070493.5A priority Critical patent/CN116178297B/en
Publication of CN116178297A publication Critical patent/CN116178297A/en
Application granted granted Critical
Publication of CN116178297B publication Critical patent/CN116178297B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A01N43/42Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/561,2-Diazoles; Hydrogenated 1,2-diazoles
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/74Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
    • A01N43/761,3-Oxazoles; Hydrogenated 1,3-oxazoles
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01PBIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P3/00Fungicides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/12Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals containing only hydrogen and carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Pest Control & Pesticides (AREA)
  • General Health & Medical Sciences (AREA)
  • Dentistry (AREA)
  • Health & Medical Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention provides a Drimane type sesquiterpene heterocyclic compound, and a preparation method and application thereof, and belongs to the technical field of organic synthesis. The Drimane type sesquiterpene heterocyclic compound provided by the invention has a structure shown in a formula I, a formula II or a formula III. According to the invention, a Drimane type sesquiterpene structure is used as a structural framework, an oxazoline group, a quinoline group or a 2H indazole group is introduced into the 11-position carbon of the Drimane type sesquiterpene, and the obtained heterocyclic compound has good antibacterial activity on various agricultural pathogenic bacteria. The results of the examples show that the Drimane type sesquiterpene heterocyclic compound provided by the invention has good bactericidal activity on Sclerotinia sclerotiorum, rhizoctonia solani and Botrytis cinerea. The invention provides a preparation method of the Drimane type sesquiterpene heterocyclic compound, which is simple to operate and suitable for industrial mass production.

Description

Drimane type sesquiterpene heterocyclic compound and preparation method and application thereof
Technical Field
The invention relates to the technical field of organic synthesis, in particular to a Drimane type sesquiterpene heterocyclic compound, and a preparation method and application thereof.
Background
The pesticide is an important means for improving and guaranteeing the grain unit yield, but the problems of increased drug resistance, environmental pollution, food safety and the like are increasingly serious due to the unscientific use of the pesticide. In the research of pesticide creation, the research conducted by taking natural products as the guide is an effective method for developing novel green pesticides. Drimane sesquiterpene compounds widely exist in nature and have biological activities of resisting tumor, resisting HIV, resisting bacteria, resisting food, etc.
Typical structures of the Drimane-like sesquiterpene compounds are as follows:
Figure BDA0004066352810000011
in recent years, research into the synthesis and biological activity of Drimane-type sesquiterpenes and analogues has been receiving increasing attention (Nat. Prod. Rep.,2004,21,449-477; microbiol cell,2020,7 (6), 146-159). However, these compounds have been less studied in agrochemical, and Drimane-type sesquiterpene heterocyclic compounds having pesticidal pathogenic bacteria inhibitory activity have been studied rarely.
Disclosure of Invention
In view of the above, the invention aims to provide a Drimane type sesquiterpene heterocyclic compound, and a preparation method and application thereof. The Drimane type sesquiterpene heterocyclic compound provided by the invention has good pesticide pathogenic bacteria inhibition activity.
In order to achieve the above object, the present invention provides the following technical solutions:
The invention provides a Drimane type sesquiterpene heterocyclic compound, which has a structure shown in a formula I, a formula II or a formula III:
Figure BDA0004066352810000021
in the formula I, the 7-8 dotted line is a double bond or the 8-9 dotted line is a double bond or the 9-12 dotted line is a double bond, and when the 7-8 dotted line is a double bond or the 8-9 dotted line is a double bond or the 9-12 dotted line is a double bond in the formula I, the rest dotted line is a single bond; heterocycles are oxazoline groups;
in the formula II, the hetercycles are oxazoline groups;
in formula III, the hetercycles are oxazoline groups, quinoline groups or 2H indazole groups.
Preferably, the oxazoline group is
Figure BDA0004066352810000022
One of the following;
the quinolinyl group is one of quinolinyl, 6-methylquinolinyl, 8-methylquinolinyl, 5-methylquinolinyl, 7-methoxyquinolinyl, 7, 8-dimethoxyquinolinyl, 6-nitroquinolinyl, 7-nitroquinolinyl, 5-chloroquinolinyl, 7-chloroquinolinyl, 6-chloro-2-methylquinolinyl, 5-fluoroquinolinyl, 6, 8-dibromoquinolinyl, 6-bromoquinolinyl, 7-trifluoromethyl quinolinyl and 6-iodoquinolinyl;
the 2H indazole group is one of 2H indazolyl, 5-bromo-2H indazolyl, 6-chloro-2H indazolyl, 4-cyano-2H indazolyl, 5-fluoro-2H indazolyl, 4-chloro-2H indazolyl, 4-trifluoromethyl-2H indazolyl, 4-methoxy-2H indazolyl, 5-methoxy-2H indazolyl, N-dimethyl-2H indazolyl and 4-methyl formate-2H indazolyl.
Preferably, in the formula I, the formula II or the formula III, the carbon atom three-dimensional configuration connected with the oxazoline group is R type or S type.
The invention provides a preparation method of the Drimane type sesquiterpene heterocyclic compound,
when the Drimane type sesquiterpene heterocyclic compound has a structure shown in a formula I, the method comprises the following steps:
(1) Under the action of diisobutyl aluminum hydride, sclareolide undergoes a reduction reaction to obtain a hemiacetal compound with a structure shown in a formula a;
under the action of boron trifluoride diethyl etherate, the hemiacetal compound with the structure shown in the formula a is subjected to hydrolysis reaction to obtainDelta having Structure shown in b 8,9 Aldehyde compounds with double bonds at the positions;
under the action of an oxidant, carrying out oxidation reaction on the compound with the structure shown in the formula b to obtain delta with the structure shown in the formula c 8,9 An acid compound having a double bond at the position;
Figure BDA0004066352810000031
(2) Performing ring-opening reaction on sclareolide and N, O-dimethylhydroxylamine hydrochloride to obtain an amide compound with a structure shown in a formula d;
the amide compound with the structure shown in the formula d is dehydrated to obtain delta with the structure shown in the formula e 8,12 Amide compounds with double bonds at the positions;
under the action of diisobutylaluminum hydride, delta with the structure shown in formula e 8,12 The reduction reaction of the amide compound with double bond at the position is carried out to obtain delta with the structure shown in the formula f 8,12 Aldehyde compounds with double bonds at the positions;
under the action of oxidant, delta with structure shown as formula f 8,12 The aldehyde compound with double bonds at the position is subjected to oxidation reaction to obtain delta with the structure shown in the formula g 8,12 An acid compound having a double bond at the position;
Figure BDA0004066352810000032
(3) Under the acidic condition, carrying out configuration conversion on sclareolide to obtain C8-S sclareolide with a structure shown in a formula h;
performing ring-opening reaction on C8-S-type sclareolide with a structure shown in formula h and N, O-dimethylhydroxylamine hydrochloride to obtain an amide compound with a structure shown in formula i;
the amide compound with the structure shown in the formula i is dehydrated to obtain delta with the structure shown in the formula j 7,8 Amide compounds with double bonds at the positions;
under the action of lithium aluminum hydride, the compound has the formulaDelta of structure shown in j 7,8 The reduction reaction of the amide compound with double bond at the position is carried out to obtain delta with the structure shown in the formula k 7,8 Aldehyde compounds with double bonds at the positions;
under the action of oxidant, delta with structure shown as formula k 7,8 Oxidizing aldehyde compound with double bond in the position to obtain delta with the structure shown in the formula I 7,8 An acid compound having a double bond at the position;
Figure BDA0004066352810000041
(4) Delta having Structure shown in c 8,9 Acid compound having double bond at position and delta having structure represented by formula g 8,12 Acid compound having double bond at position or delta having structure represented by formula l 7,8 Performing condensation reaction on the acid compound with the double bond at the position and the chiral amino alcohol compound to obtain an amide alcohol intermediate;
under the action of diethylaminosulfur trifluoride, the amide alcohol intermediate undergoes cyclization reaction to obtain a Drimane type sesquiterpene heterocyclic compound with a structure shown in a formula I;
(II) when the Drimane type sesquiterpene heterocyclic compound has a structure shown in a formula II, the method comprises the following steps:
under the catalysis of ruthenium trichloride, sclareol and an oxidant are subjected to oxidation reaction to obtain an intermediate acid with a structure shown in a formula m;
Figure BDA0004066352810000042
performing condensation reaction on the intermediate acid with the structure shown in the formula m and a chiral amino alcohol compound to obtain an amide alcohol intermediate;
under the action of diethylaminosulfur trifluoride, the amide alcohol intermediate undergoes cyclization reaction to obtain a Drimane type sesquiterpene heterocyclic compound with a structure shown in a formula II;
(III) when the Drimane type sesquiterpene heterocyclic compound has a structure shown in a formula III, the method comprises the following steps:
(i) When the hetercycles are oxazoline groups, comprising the steps of:
Under the action of organic alkali, carrying out hydrolysis reaction on the Drimane type sesquiterpene heterocyclic compound with the structure shown in the formula II to obtain the Drimane type sesquiterpene heterocyclic compound with the structure shown in the formula III;
(ii) When the hetercycles are quinolines, the method comprises the steps of:
performing ring-opening reaction on sclareolide and methyl lithium to obtain an intermediate ketone compound with a structure shown in formula n;
Figure BDA0004066352810000051
performing a Friedel-crafts quinoline synthesis reaction on an intermediate ketone compound with a structure shown in a formula n and a 2-aminobenzaldehyde compound to obtain a Drimane type sesquiterpene heterocyclic compound with a structure shown in a formula III;
(iii) When the hetercycles are 2H indazole groups, the method comprises the following steps:
sclareolide and NH under the catalysis of sodium methoxide 3 Carrying out ammonolysis reaction to obtain a compound with a structure shown in a formula o;
under alkaline conditions, carrying out Huffman rearrangement reaction on the compound with the structure shown in the formula o to obtain a compound with the structure shown in the formula p;
Figure BDA0004066352810000052
under the action of diethylenetriamine, carrying out alkaline hydrolysis reaction on a compound with a structure shown in a formula p to obtain an intermediate amine compound with a structure shown in a formula q;
under the action of tri-n-butyl phosphine, an intermediate amine compound with a structure shown in a formula q and a 2-nitrobenzaldehyde compound undergo a reduction cyclization reaction to obtain a Drimane type sesquiterpene heterocyclic compound with a structure shown in a formula III.
Preferably, in the step (1) in the step (one), the temperature of the reduction reaction is-80 to-60 ℃;
the oxidant is sodium chlorite;
in the step (2) in the step (one), the temperature of the ring-opening reaction is-10-35 ℃;
the catalyst for the dehydration reaction is thionyl chloride and pyridine, and the temperature of the dehydration reaction is-80 to-60 ℃;
the temperature of the reduction reaction is-80 to-60 ℃;
the oxidant is sodium chlorite;
in the step (3) of the step (one), the temperature of the ring-opening reaction is-10-35 ℃;
the catalyst for the dehydration reaction is thionyl chloride and pyridine, and the temperature of the dehydration reaction is-20 ℃;
the temperature of the reduction reaction is-80 to-60 ℃;
the oxidant is sodium chlorite;
in the step (4) of the step (one), the temperature of the condensation reaction is 0-room temperature;
the temperature of the cyclization reaction is-80 to-60 ℃.
Preferably, in the step (two), the temperature of the oxidation reaction is 40 ℃;
the temperature of the condensation reaction is 0-room temperature;
the temperature of the cyclization reaction is-80 to-60 ℃.
Preferably, in step (i) of the step (three), the hydrolysis reaction temperature is 0 to reflux temperature;
In the step (ii) of the step (three), the temperature of the ring-opening reaction is-80 to-60 ℃;
the temperature of the synthesis reaction of the friedel-crafts quinoline is room temperature;
in the step (iii) of the step (III), the temperature of the ammonolysis reaction is 40-80 ℃;
the temperature of the Huffman rearrangement reaction is 0-room temperature;
the temperature of the alkaline hydrolysis reaction is 120-160 ℃;
the reaction temperature of the reductive cyclization is 60-100 ℃.
The invention provides application of the Drimane type sesquiterpene heterocyclic compound in resisting agricultural pathogenic bacteria.
Preferably, the method comprises the steps of, the agricultural pathogenic bacteria are one or more of Rhizoctonia solani, rhizoctonia cerealis, sclerotinia sclerotiorum, alternaria cerealis, leucomatous solani, phytophthora capsici, phytophthora solani, phytophthora capsici, phytophthora oryzae, dry rot of potato, anthracnose of cucumber and Pyricularia oryzae.
The invention provides a Drimane type sesquiterpene heterocyclic compound, which has a structure shown in a formula I, a formula II or a formula III. Drug similarity of compounds is a key factor in the initial stage of drug discovery, drug similarity parameter sp 3 Percentage of hybridized carbon (fractionofsp) 3 carbons,Fsp 3 ) Is an important parameter of the drug similarity, and the average Fsp of the marketed molecules 3 The commercial bactericides at 0.45 mostly contain flat aromatic rings, fsp 3 The value is low, and all carbon atoms on the Drimane sesquiterpene skeleton of the rigid structure are sp 3 After hybridization, the aromatic group is connected to achieve a balance, so that the patentability of the compound is improved. According to the invention, a Drimane type sesquiterpene structure is used as a structural framework, an oxazoline group, a quinoline group or a 2H indazole group is introduced into the 11-position carbon of the Drimane type sesquiterpene, and the obtained heterocyclic compound has good antibacterial activity on various agricultural pathogenic bacteria. The results of the examples show that the Drimane type sesquiterpene heterocyclic compound provided by the invention has good bactericidal activity on Sclerotinia sclerotiorum, rhizoctonia solani and Botrytis cinerea.
The invention provides a preparation method of the Drimane type sesquiterpene heterocyclic compound, which is simple to operate and suitable for industrial mass production.
Detailed Description
The invention provides a Drimane type sesquiterpene heterocyclic compound, which has a structure shown in a formula I, a formula II or a formula III:
Figure BDA0004066352810000071
in the formula I, the 7-8 dotted line is a double bond or the 8-9 dotted line is a double bond or the 9-12 dotted line is a double bond, and when the 7-8 dotted line is a double bond or the 8-9 dotted line is a double bond or the 9-12 dotted line is a double bond in the formula I, the rest dotted line is a single bond; heterocycles are oxazoline groups;
In the formula II, the hetercycles are oxazoline groups;
in formula III, the hetercycles are oxazoline groups, quinoline groups or 2H indazole groups.
In the present invention, the oxazoline group is preferably
Figure BDA0004066352810000081
One of them.
In the present invention, the quinoline group is preferably
Figure BDA0004066352810000082
The quinoline group is one of quinolinyl, 6-methylquinolinyl, 8-methylquinolinyl, 5-methylquinolinyl, 7-methoxyquinolinyl, 7, 8-dimethoxyquinolinyl, 6-nitroquinolinyl, 7-nitroquinolinyl, 5-chloroquinolinyl, 7-chloroquinolinyl, 6-chloro-2-methylquinolinyl, 5-fluoroquinolinyl, 6, 8-dibromoquinolinyl, 6-bromoquinolinyl, 7-trifluoromethyl quinolinyl and 6-iodoquinolinyl.
In the present invention, the 2H indazole group is
Figure BDA0004066352810000091
The 2H indazole group is one of 2H indazolyl, 5-bromo-2H indazolyl, 6-chloro-2H indazolyl, 4-cyano-2H indazolyl, 5-fluoro-2H indazolyl, 4-chloro-2H indazolyl, 4-trifluoromethyl-2H indazolyl, 4-methoxy-2H indazolyl, 5-methoxy-2H indazolyl, N-dimethyl-2H indazolyl and 4-methyl formate-2H indazolyl.
In the present invention, the
Figure BDA0004066352810000092
Meaning of (c) means the ligation site.
In the present invention, in the formula I, formula II or formula III, the carbon atom steric configuration attached to the oxazoline group is preferably R-type or S-type.
As a specific example of the invention, the structural formula of the Drimane type sesquiterpene heterocyclic compound is shown in table 1.
TABLE 1 partial structural formula of Drimane type sesquiterpene heterocycles
Figure BDA0004066352810000093
Figure BDA0004066352810000101
In the invention, the preparation method of the Drimane type sesquiterpene heterocyclic compound comprises the following steps:
when the Drimane type sesquiterpene heterocyclic compound has a structure shown in a formula I, the preparation method comprises the following steps:
(1) Under the action of diisobutyl aluminum hydride, sclareolide undergoes a reduction reaction to obtain a hemiacetal compound with a structure shown in a formula a;
under the action of boron trifluoride diethyl etherate, the hemiacetal compound with the structure shown in the formula a undergoes hydrolysis reaction to obtain delta with the structure shown in the formula b 8,9 Aldehyde compounds with double bonds at the positions;
under the action of oxidantThe compound having the structure shown in formula b is subjected to oxidation reaction to obtain delta having the structure shown in formula c 8,9 An acid compound having a double bond at the position;
Figure BDA0004066352810000102
(2) Performing ring-opening reaction on sclareolide and N, O-dimethylhydroxylamine hydrochloride to obtain an amide compound with a structure shown in a formula d;
The amide compound with the structure shown in the formula d is dehydrated to obtain delta with the structure shown in the formula e 8,12 Amide compounds with double bonds at the positions;
under the action of diisobutylaluminum hydride, delta with the structure shown in formula e 8,12 The reduction reaction of the amide compound with double bond at the position is carried out to obtain delta with the structure shown in the formula f 8,12 Aldehyde compounds with double bonds at the positions;
under the action of oxidant, delta with structure shown as formula f 8,12 The aldehyde compound with double bonds at the position is subjected to oxidation reaction to obtain delta with the structure shown in the formula g 8,12 An acid compound having a double bond at the position;
Figure BDA0004066352810000111
(3) Under the acidic condition, carrying out configuration conversion on sclareolide to obtain C8-S sclareolide with a structure shown in a formula h;
performing ring-opening reaction on C8-S-type sclareolide with a structure shown in formula h and N, O-dimethylhydroxylamine hydrochloride to obtain an amide compound with a structure shown in formula i;
the amide compound with the structure shown in the formula i is dehydrated to obtain delta with the structure shown in the formula j 7,8 Amide compounds with double bonds at the positions;
under the action of lithium aluminum hydride, delta with the structure shown in formula j 7,8 The reduction reaction of the amide compound with double bond at the position is carried out to obtain delta with the structure shown in the formula k 7,8 Aldehyde compounds with double bonds at the positions;
Under the action of oxidant, delta with structure shown as formula k 7,8 Oxidizing aldehyde compound with double bond in the position to obtain delta with the structure shown in the formula I 7,8 An acid compound having a double bond at the position;
Figure BDA0004066352810000112
(4) Delta having Structure shown in c 8,9 Acid compound having double bond at position and delta having structure represented by formula g 8,12 Acid compound having double bond at position or delta having structure represented by formula l 7,8 Performing condensation reaction on the acid compound with the double bond at the position and the chiral amino alcohol compound to obtain an amide alcohol intermediate;
under the action of diethylaminosulfur trifluoride, the amide alcohol intermediate undergoes cyclization reaction to obtain the Drimane type sesquiterpene heterocyclic compound with the structure shown in the formula I.
According to the invention, sclareolide undergoes a reduction reaction under the action of diisobutylaluminum hydride to obtain a hemiacetal compound with a structure shown in a formula a. In the present invention, the organic solvent used for the reduction reaction is preferably methylene chloride. In the present invention, the temperature of the reduction reaction is preferably-78 ℃; the molar ratio of sclareolide to diisobutylaluminum hydride is preferably 1:1.2-2, more preferably 1:1.5.
Under the action of boron trifluoride diethyl etherate, the hemiacetal compound with the structure shown in the formula a undergoes hydrolysis reaction to obtain delta with the structure shown in the formula b 8,9 Aldehyde compounds with double bonds at the positions. In the present invention, the organic solvent used for the hydrolysis reaction is preferably methylene chloride. In the present invention, the temperature of the hydrolysis reaction is preferably 10 to 30 ℃, more preferably 15 to 25 ℃; the molar ratio of the hemiacetal compound with the structure shown in the formula a to the boron trifluoride diethyl etherate is preferably 1:1.1-1.5.
Under the action of an oxidant, the compound with the structure shown in the formula b undergoes oxidation reaction to obtain the compound with the structure shown in the formula cDelta of (2) 8,9 Acid compounds with double bonds in the positions. In the present invention, the oxidizing agent is preferably sodium chlorite.
In the present invention, the solvent used in the oxidation reaction is preferably a mixed solution of tetrahydrofuran, t-butanol and water; in the present invention, the temperature of the oxidation reaction is preferably 10 to 30 ℃, more preferably 15 to 25 ℃, and the molar ratio of the compound having the structure represented by formula b to the oxidizing agent is preferably 1:2.5 to 3.5.
In the present invention, the structure of formula c is defined as delta 8,9 The synthetic route of the acid compound with double bond at the position is shown as the formula (1):
Figure BDA0004066352810000121
in the invention, sclareolide and N, O-dimethylhydroxylamine hydrochloride undergo a ring-opening reaction to obtain an amide compound with a structure shown in a formula d. In the present invention, the organic solvent for the ring-opening reaction is preferably tetrahydrofuran. In the present invention, the temperature of the ring-opening reaction is preferably-10 to 35 ℃, more preferably 0 to room temperature; the molar ratio of sclareolide to N, O-dimethylhydroxylamine hydrochloride is preferably 1:2-5, more preferably 1:3-4.
In the present invention, the amide compound having the structure represented by formula d undergoes a dehydration reaction to give a delta compound having the structure represented by formula e 8,12 Amide compounds with double bonds at the positions. In the present invention, the dehydration reaction is preferably performed under thionyl chloride and pyridine conditions. In the present invention, the organic solvent used in the dehydration reaction is preferably methylene chloride; the temperature of the dehydration reaction is preferably-80 to-60 ℃, more preferably-78 ℃.
In the present invention, under the action of diisobutylaluminum hydride, delta having the structure shown in formula e 8,12 The reduction reaction of the amide compound with double bond at the position is carried out to obtain delta with the structure shown in the formula f 8,12 Aldehyde compounds with double bonds at the positions. In the present invention, the organic solvent used in the reduction reaction is preferably tetrahydrofuran; the temperature of the reduction reaction is preferably-80 to-60 ℃, more preferably-78 ℃; in the present invention, the structure of formula e is shown as delta 8,12 The molar ratio of the double bond amide compound to diisobutyl aluminum hydride is preferably 1:1.1-2.
In the present invention, under the action of an oxidizing agent, a having a structure represented by formula f 8,12 The aldehyde compound with double bonds at the position is subjected to oxidation reaction to obtain delta with the structure shown in the formula g 8,12 Acid compounds with double bonds in the positions. In the present invention, the oxidizing agent is preferably sodium chlorite; in the present invention, the solvent used in the oxidation reaction is preferably a mixed solution of tetrahydrofuran, t-butanol and water; in the present invention, the temperature of the oxidation reaction is preferably 10 to 30 ℃, more preferably 15 to 25 ℃; the molar ratio of the compound having the structure represented by formula b to the oxidizing agent is preferably 1:2.5 to 3.5, more preferably 1:3.
In the present invention, the formula [ delta ] has a structure represented by formula g 8,12 The synthetic route of the acid compound with double bond at the position is shown as the formula (2):
Figure BDA0004066352810000131
under the acidic condition, the sclareolide is subjected to configuration conversion to obtain the C8-S sclareolide with the structure shown in the formula h. In the present invention, the acid providing the acidic condition is preferably concentrated sulfuric acid and formic acid, and the volume ratio of the concentrated sulfuric acid to the formic acid is preferably 7:170. In the present invention, the configuration conversion is preferably performed under room temperature conditions.
In the invention, C8-S type sclareolide with a structure shown in a formula h and N, O-dimethylhydroxylamine hydrochloride undergo a ring-opening reaction to obtain an amide compound with a structure shown in a formula i. In the present invention, the organic solvent used in the ring-opening reaction is preferably tetrahydrofuran; in the present invention, the temperature of the ring-opening reaction is preferably-10 to 35 ℃, more preferably 0 to room temperature. In the present invention, the molar ratio of the C8-S type sclareolide having the structure represented by formula h to N, O-dimethylhydroxylamine hydrochloride is preferably 1:2 to 5, more preferably 1:3 to 4.
In the present invention, the amide compound having the structure represented by formula i undergoes a dehydration reaction to give a delta compound having the structure represented by formula j 7,8 Amide compounds with double bonds at the positions. In the present invention, the dehydration reaction is preferably performed under thionyl chloride and pyridine conditions. In the present invention, the organic solvent used in the dehydration reaction is preferably methylene chloride; the temperature of the dehydration reaction is preferably-20 to 20 ℃, more preferably 0 ℃.
In the present invention, under the action of lithium aluminum hydride, delta with the structure shown in formula j 7,8 The reduction reaction of the amide compound with double bond at the position is carried out to obtain delta with the structure shown in the formula k 7,8 Aldehyde compounds with double bonds at the positions. In the present invention, the organic solvent used in the reduction reaction is preferably tetrahydrofuran; in the present invention, the temperature of the reduction reaction is preferably 0 ℃; in the present invention, the formula [ delta ] has a structure represented by formula [ j ] 7,8 The molar ratio of the amide compound having a double bond in position to lithium aluminum hydride is preferably 1:2 to 5, more preferably 1:3 to 4.
In the present invention, a having a structure represented by formula k is represented by delta under the action of an oxidizing agent 7,8 Oxidizing aldehyde compound with double bond in the position to obtain delta with the structure shown in the formula I 7,8 Acid compounds with double bonds in the positions. In the present invention, the oxidizing agent is preferably sodium chlorite; in the present invention, the solvent used in the oxidation reaction is preferably a mixed solution of tetrahydrofuran, t-butanol and water; in the present invention, the temperature of the oxidation reaction is preferably 10 to 30 ℃, more preferably 15 to 25 ℃; in the present invention, the structure of formula k is shown as delta 7,8 The molar ratio of the aldehyde compound having a double bond in position to the oxidizing agent is preferably 1:2.5 to 3.5, more preferably 1:3.
In the present invention, Δ having the structure represented by formula l 7,8 The synthetic route of the acid compound with double bond at the position is shown as a formula (3):
Figure BDA0004066352810000141
in the present invention, Δ having a structure represented by formula c 8,9 Acid compound having double bond at position and delta having structure represented by formula g 8 , 12 Acid compound having double bond at position or delta having structure represented by formula l 7,8 And (3) carrying out condensation reaction on the acid compound with the double bond at the position and the chiral amino alcohol compound to obtain an amide alcohol intermediate. In the invention, the structural general formula of the chiral amino alcohol compound is preferably that
Figure BDA0004066352810000151
R represents a substitutable substituent; in the present invention, the condensation reaction is preferably performed in the presence of 4-dimethylaminopyridine and carbodiimide (EDCI). In the present invention, the organic solvent used for the condensation reaction is preferably methylene chloride. In the present invention, the temperature of the condensation reaction is preferably 0 to room temperature.
In the invention, under the action of diethylaminosulfur trifluoride, the amide alcohol intermediate is subjected to cyclization reaction to obtain the Drimane type sesquiterpene heterocyclic compound with the structure shown in the formula I. In the present invention, the organic solvent used in the cyclization reaction is preferably methylene chloride. In the present invention, the temperature of the cyclization reaction is preferably-80 to-60 ℃, more preferably-78 ℃; in the present invention, the molar ratio of the amide alcohol intermediate to diethylaminosulfur trifluoride is preferably 1:2.5 to 3.5, more preferably 1:3.
In the invention, when the Drimane type sesquiterpene heterocyclic compound has a structure shown in a formula II, the method comprises the following steps:
under the catalysis of ruthenium trichloride, sclareol and an oxidant are subjected to oxidation reaction to obtain an intermediate acid with a structure shown in a formula m;
Figure BDA0004066352810000152
performing condensation reaction on the intermediate acid with the structure shown in the formula m and a chiral amino alcohol compound to obtain an amide alcohol intermediate;
under the action of diethylaminosulfur trifluoride, the amide alcohol intermediate undergoes cyclization reaction to obtain the Drimane type sesquiterpene heterocyclic compound with the structure shown in the formula II.
In the invention, sclareol and an oxidant are subjected to oxidation reaction under the catalysis of ruthenium trichloride to obtain an intermediate acid with a structure shown in a formula m. In the present invention, the oxidizing agent is preferably sodium periodate. In the present invention, the solvent used in the oxidation reaction is preferably a mixed solution of carbon tetrachloride, acetonitrile and water; in the present invention, the temperature of the oxidation reaction is preferably 40 ℃; the molar ratio of sclareol to catalyst and oxidant is preferably 1:12:0.05.
In the invention, the synthesis route of the intermediate acid with the structure shown in the formula m is shown as a formula (4):
Figure BDA0004066352810000161
In the invention, intermediate acid with a structure shown in a formula m and chiral amino alcohol compounds are subjected to condensation reaction to obtain an amide alcohol intermediate. In the invention, the structural general formula of the chiral amino alcohol compound is preferably that
Figure BDA0004066352810000162
R represents a substitutable substituent; in the present invention, the condensation reaction is preferably performed in the presence of 4-dimethylaminopyridine and carbodiimide (EDCI). In the present invention, the organic solvent used for the condensation reaction is preferably methylene chloride. In the present invention, the temperature of the condensation reaction is preferably 0 to room temperature.
In the invention, under the action of diethylaminosulfur trifluoride, the amide alcohol intermediate is subjected to cyclization reaction to obtain the Drimane type sesquiterpene heterocyclic compound with the structure shown in the formula II. In the present invention, the organic solvent used in the cyclization reaction is preferably methylene chloride; the temperature of the cyclization reaction is preferably-80 to-60 ℃, more preferably-78 ℃; in the present invention, the molar ratio of the amide alcohol intermediate to diethylaminosulfur trifluoride is preferably 1:2.5 to 3.5, more preferably 1:3.
In the invention, the synthetic route of the Drimane type sesquiterpene heterocyclic compound with the structure shown in the formula II is shown in the formula (5):
Figure BDA0004066352810000163
In the invention, when the Drimane type sesquiterpene heterocyclic compound has a structure shown in a formula III, the method comprises the following steps:
(i) When the hetercycles are oxazoline groups, comprising the steps of:
under the action of organic alkali, carrying out hydrolysis reaction on the Drimane type sesquiterpene heterocyclic compound with the structure shown in the formula II to obtain the Drimane type sesquiterpene heterocyclic compound with the structure shown in the formula III;
(ii) When the hetercycles are quinolines, the method comprises the steps of:
performing ring-opening reaction on sclareolide and methyl lithium to obtain an intermediate ketone compound with a structure shown in formula n;
Figure BDA0004066352810000171
performing a Friedel-crafts quinoline synthesis reaction on an intermediate ketone compound with a structure shown in a formula n and a 2-aminobenzaldehyde compound to obtain a Drimane type sesquiterpene heterocyclic compound with a structure shown in a formula III;
(iii) When the hetercycles are 2H indazole groups, the method comprises the following steps:
sclareolide and NH under the catalysis of sodium methoxide 3 Carrying out ammonolysis reaction to obtain a compound with a structure shown in a formula o;
under alkaline conditions, carrying out Huffman rearrangement reaction on the compound with the structure shown in the formula o to obtain a compound with the structure shown in the formula p;
Figure BDA0004066352810000172
Under the action of diethylenetriamine, carrying out alkaline hydrolysis reaction on a compound with a structure shown in a formula p to obtain an intermediate amine compound with a structure shown in a formula q;
under the action of tri-n-butyl phosphine, an intermediate amine compound 2-nitrobenzaldehyde compound with a structure shown in a formula q is subjected to reduction cyclization reaction to obtain a Drimane type sesquiterpene heterocyclic compound with a structure shown in a formula III.
In the present invention, when the hetercycles are oxazoline groups, the steps are as follows:
under the action of organic alkali, the Drimane type sesquiterpene heterocyclic compound with the structure shown in the formula II is subjected to hydrolysis reaction to obtain the Drimane type sesquiterpene heterocyclic compound with the structure shown in the formula III. In the present invention, the organic strong base is preferably potassium hydroxide. In the present invention, the organic solvent used in the hydrolysis reaction is preferably methanol. In the present invention, the temperature of the hydrolysis reaction is preferably 0 to reflux temperature. In the invention, the synthetic route of the Drimane type sesquiterpene heterocyclic compound with the structure shown in the formula III is shown in the formula (6):
Figure BDA0004066352810000173
in the present invention, when the Heterocycles are quinoline groups, the method comprises the steps of:
The sclareolide and methyl lithium undergo a ring-opening reaction to obtain an intermediate ketone compound with a structure shown in a formula n. In the present invention, the organic solvent used in the ring-opening reaction is preferably diethyl ether. In the present invention, the temperature of the ring-opening reaction is preferably-80 to-60 ℃, more preferably-78 ℃; the molar ratio of sclareolide to methyllithium is preferably 1:2.3-3.5, more preferably 1:2.5-3. In the invention, the synthetic route of the intermediate ketone compound with the structure shown in the formula n is shown in the formula (7):
Figure BDA0004066352810000181
in the invention, intermediate ketone compounds with a structure shown in a formula n and 2-aminobenzaldehyde compounds are subjected to a Foldebrand quinoline synthesis reaction to obtain Drimane type sesquiterpene heterocyclic compounds with a structure shown in a formula III. In the invention, the structural general formula of the 2-aminobenzaldehyde compound is
Figure BDA0004066352810000182
R represents a substitutable substituent.
In the present invention, the friedel-crafts quinoline synthesis reaction is preferably performed under an alkaline environment, and the alkaline reagent providing the alkaline environment is preferably potassium hydroxide. In the present invention, the organic solvent used in the synthesis reaction of the friedel-crafts quinoline is preferably ethanol. In the present invention, the temperature of the friedel-crafts quinoline synthesis reaction is preferably room temperature. In the invention, the molar ratio of the intermediate ketone compound with the structure shown in the formula n to the 2-aminobenzaldehyde compound is preferably 0.5-1.5:1, and more preferably 1:1. In the invention, the synthetic route of the Drimane type sesquiterpene heterocyclic compound with the structure shown in the formula III is shown in the formula (8).
Figure BDA0004066352810000183
In the present invention, when the hetercycles are 2H indazole-type groups, the steps are included as follows:
sclareolide and NH under the catalysis of sodium methoxide 3 Ammonolysis reaction is carried out to obtain the compound with the structure shown in the formula o. In the present invention, the organic solvent used in the ammonolysis reaction is preferably methanol; in the present invention, the temperature of the ammonolysis reaction is preferably 40 to 80 ℃, more preferably 60 ℃; the sclareolide and NH 3 The molar ratio of (2) is preferably 1:7 to 10.
In the invention, under alkaline conditions, a compound with a structure shown in a formula o undergoes a Hofmann rearrangement reaction to obtain a compound with a structure shown in a formula p. In the present invention, the alkaline agent providing the alkaline environment is preferably potassium hydroxide. In the present invention, the hofmann rearrangement reaction is preferably performed under iodobenzene diacetic acid PIDA conditions; the PIDA plays an oxidizing role. In the present invention, the temperature of the hofmann rearrangement reaction is preferably 0 to room temperature.
In the invention, under the action of diethylenetriamine, a compound with a structure shown in a formula p is subjected to alkaline hydrolysis reaction to obtain an intermediate amine compound with a structure shown in a formula q. In the present invention, the temperature of the alkaline hydrolysis reaction is preferably 120 to 160 ℃, more preferably 140 ℃; the molar ratio of the compound having the structure represented by formula p to diethylenetriamine is preferably 1:20-25.
In the invention, the synthetic route of the intermediate amine compound with the structure shown in the formula q is shown as a formula (9):
Figure BDA0004066352810000191
in the invention, under the action of tri-n-butyl phosphine, an intermediate amine compound with a structure shown in a formula q and a 2-nitrobenzaldehyde compound undergo a reductive cyclization reaction to obtain a Drimane type sesquiterpene heterocyclic compound with a structure shown in a formula III. In the invention, the structural general formula of the 2-nitrobenzaldehyde compound is
Figure BDA0004066352810000192
R represents a substitutable substituent.
In the present invention, the temperature of the reductive cyclization reaction is preferably 60 to 100 ℃, more preferably 80 ℃; the molar ratio of the intermediate amine compound with the structure shown in the formula q to tri-n-butyl phosphine is preferably 1:3-4. In the invention, the synthetic route of the Drimane type sesquiterpene heterocyclic compound with the structure shown in the formula III is shown in the formula I.
Figure BDA0004066352810000193
The invention provides an application of the Drimane type sesquiterpene heterocyclic compound or the Drimane type sesquiterpene heterocyclic compound prepared by the preparation method in resisting agricultural pathogenic bacteria.
In the present invention, the agricultural pathogenic bacteria are preferably one or more species of Rhizoctonia solani (Rhizoctonia solani), rhizoctonia cerealis (Rhizoctonia cerealis), sclerotinia sclerotiorum (Sclerotinia sclerotiorum), rhizoctonia cerealis (Fusarium graminearum), rhizoctonia cerealis (Gaeumatopsis), botrytis cinerea (Botrytis cinerea), phytophthora infestans (Phytophthora infestans), phytophthora capsici (Phytophthora capsici), phytophthora capsici (Alternaria asacola), rhizoctonia solani (Fusarium fujikuri), solanum sativum (Fusarium sulphureum), cucumidis sativus anthracis (Colletotrichlainium) and Pyricularia oryzae (Phyricularia cerealis).
The Drimane type sesquiterpene heterocyclic compounds, the preparation method and application thereof provided by the invention are described in detail below with reference to examples, but are not to be construed as limiting the scope of the invention.
Example 1
Figure BDA0004066352810000201
Sclareolide (10 g,32.4 mmol) was weighed and dissolved in a mixture of acetonitrile (21 mL) and carbon tetrachloride (21 mL), ruthenium trichloride trihydrate (428 mg,1.62 mmol) was weighed in a 500mL round bottom flask, sodium periodate (83.0 g, 3838 mmol) was dissolved in a mixture of water (84 mL), carbon tetrachloride (42 mL) and acetonitrile (42 mL), the mixture was heated to 40℃and sclareolide solution was slowly dropped into the mixture, the mixture was stirred at 40℃for 5 hours, ethyl acetate (300 mL) was added after cooling to room temperature, washed successively with water (100 mL. Times.3), sodium thiosulfate aqueous solution (100 mL. Times.3) and saturated sodium chloride aqueous solution (100 mL. Times.3), the aqueous phase was extracted with ethyl acetate (100 mL. Times.3), the organic phases were combined, dried, concentrated under reduced pressure, and after silica gel column chromatography (elution)The preparation method comprises the following steps: v (V) Petroleum ether /V Acetic acid ethyl ester =5:1-2:1) to give ACID-OAc as a white solid in 55% yield.
ACID-OAc (470 mg,1.5 mmol) was dissolved in dichloromethane (20 mL), 4-dimethylaminopyridine (38.0 mg,0.3 mmol) and phenylglycinol (315 mg,2.3 mmol) were added, then the above system was transferred to ice bath and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (382 mg,2.0 mmol) was added, stirred at room temperature, monitored by TLC tracking, after completion of the reaction, the organic phase was washed with water, saturated sodium chloride solution, respectively, and dried over anhydrous sodium sulfate, and the mixture was concentrated. After silica gel column chromatography (eluent: V) Petroleum ether /V Acetic acid ethyl ester =1: 1) AD-1 was obtained as a white solid in 68% yield.
1 HNMR(500MHz,CDCl 3 )δ7.37–7.33(m,2H),7.31–7.27(m,3H),6.31(d,J=6.7Hz,1H),5.03(td,J=6.4,3.8Hz,1H),3.92–3.85(m,2H),2.72–2.66(m,1H),2.42–2.36(m,1H),2.25–2.18(m,2H),1.80(s,3H),1.75–1.65(m,2H),1.58–1.49(m,2H),1.45(s,3H),1.41–1.31(m,2H),1.30–1.19(m,1H),1.18–1.03(m,2H),1.01–0.93(m,1H),0.85(s,3H),0.82(s,3H),0.76(s,3H).
13 CNMR(126MHz,CDCl 3 )δ174.96,170.45,139.14,129.09,128.17,126.92,87.31,67.25,56.58,56.01,55.53,41.70,39.24,39.19,38.86,33.36,33.21,22.82,21.52,20.39,20.00,18.23,15.75.
The amidol AD-1 (399mg, 0.9 mmol) was added to a Schlenk tube equipped with a magnetic stirrer, nitrogen was replaced 3 times, methylene chloride was added to dissolve and transfer to-78deg.C, diethylaminosulfur trifluoride (340 μL,2.8 mmol) was slowly added dropwise, the dropwise addition was completed and the reaction was stirred at-78deg.C, followed by TLC monitoring, after completion of the reaction, the reaction was quenched with water, washed with saturated sodium carbonate solution, the organic phase was dried over anhydrous sodium sulfate, and the mixture was concentrated. After silica gel column chromatography (eluent: V) Petroleum ether /V Acetic acid ethyl ester =10: 1) Oxazoline OZ-1 was obtained as a white solid in 66% yield.
1 HNMR(500MHz,CDCl 3 )δ7.35–7.31(m,2H),7.28–7.23(m,3H),5.16(dd,J=10.1,8.4Hz,1H),4.61(dd,J=10.2,8.4Hz,1H),4.08(t,J=8.4Hz,1H),2.69(dt,J=12.7,3.4Hz,1H),2.53(m,,1H),2.45(m,1H),2.32(dd,J=6.3,4.0Hz,1H),1.86(s,3H),1.83–1.76(m,1H),1.71–1.65(m,2H),1.63–1.53(m,1H),1.50(s,3H),1.46–1.40(m,1H),1.39–1.34(m,1H),1.32–1.23(m,1H),1.18–1.08(m,3H),0.89(s,3H),0.86(s,3H),0.79(s,3H).
13 CNMR(126MHz,CDCl 3 )δ170.38,170.07,142.64,128.73,127.57,126.78,86.56,74.62,69.70,55.27,55.07,41.75,39.31,39.25,38.66,33.46,33.23,24.52,23.09,21.58,20.35,19.99,18.45,15.50.
Weighing oxazoline OZ-1 (207 mg,0.54 mmol) into pear-shaped bottle, adding methanol (25 mL) for dissolution, adding potassium hydroxide (423 mg,7.56 mmol) at 0 ℃, refluxing the reaction system, tracking and monitoring by TLC, adding 1MHCl to adjust PH=7-8 at 0 ℃ after the reaction is complete, extracting with ethyl acetate (25 mL multiplied by 2), washing with water (30 mL), saturated sodium chloride aqueous solution (30 mL) in sequence, drying with anhydrous sodium sulfate, evaporating solvent under reduced pressure, and performing silica gel column chromatography (eluent: V) Petroleum ether /V Acetic acid ethyl ester =3: 1) Obtained as a white solid in 58% yield.
1 HNMR(500MHz,CDCl 3 )δ7.34–7.31(m,2H),7.28–7.20(m,3H),5.12(t,J=9.3Hz,1H),4.60(dd,J=10.3,8.1Hz,1H),4.09–4.04(m,1H),2.58–2.53(m,1H),2.40(dd,J=16.9,4.6Hz,1H)1.96–1.89(m,2H),1.70–1.63(m,2H),1.60–1.54(m,1H),1.51–1.41(m,2H),1.38–1.34(m,1H),1.30–1.21(m,1H),1.16(s,3H),1.15–0.99(m,3H),0.86(s,3H),0.82(s,3H),0.79(s,3H).
13 CNMR(126MHz,CDCl 3 )δ171.68,142.43,128.81,127.97,127.64,126.78,125.92,75.04,73.32,69.46,58.12,55.85,44.42,41.83,39.50,38.97,33.47,33.38,23.79,23.48,21.59,20.56,18.58,15.35.
Example 2
Figure BDA0004066352810000221
ACID-89 (406 mg,1.6 mmol) was dissolved in dichloromethane (20 mL) and 4-dimethyl was addedAminopyridine (40 mg,0.33 mmol) and phenylalaninol (365 mg,2.4 mmol) were then transferred to ice bath and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (405 mg,2.4 mmol) was added, stirred at room temperature, monitored by TLC tracking, after completion of the reaction, washed with water, saturated sodium chloride solution, respectively, the organic phase was dried over anhydrous sodium sulfate, and the mixture was concentrated. After silica gel column chromatography (eluent: V) Petroleum ether /V Acetic acid ethyl ester =3: 1) AD-9-1 was obtained as a colorless oil in 60% yield.
1 HNMR(400MHz,CDCl 3 )δ7.33–7.27(m,2H),7.25–7.16(m,3H),6.10(d,J=6.8Hz,1H),4.19–4.10(m,1H),3.62(dd,J=4.9,1.4Hz,2H),3.00–2.93(m,1H),2.92–2.76(m,3H),2.06–1.91(m,2H),1.70–1.61(m,2H),1.58–1.45(m,1H),1.45–1.33(m,6H(s,3H)),1.08–0.92(m,3H),0.89(s,3H),0.84(s,3H),0.81(s,3H).
13 CNMR(101MHz,CDCl 3 )δ172.73,137.15,135.40,131.89,129.30,128.79,126.86,64.64,53.08,51.88,41.65,38.69,36.81,36.05,35.94,33.36,33.34,33.23,21.62,19.95,19.88,18.80,18.78.
AD-9-1 (284 mg,0.75 mmol) was added to a Schlenk tube equipped with a magnetic stirrer, nitrogen was replaced 3 times, methylene chloride was added to dissolve and transfer to-78deg.C, diethylaminosulfur trifluoride (275 μL,2.2 mmol) was slowly added dropwise, the reaction was stirred at-78deg.C after the addition was completed, TLC was followed by monitoring, after the reaction was completed, the reaction was quenched with water, washed with saturated sodium carbonate solution, the organic phase was dried over anhydrous sodium sulfate, and the mixture was concentrated. After silica gel column chromatography (eluent: V) Petroleum ether /V Acetic acid ethyl ester =20: 1) OZ-9-1 was obtained as colorless oil in 50% yield.
1 HNMR(400MHz,CDCl 3 )δ7.31–7.26(m,2H),7.23–7.17(m,3H),4.38–4.28(m,1H),4.10(t,J=8.9Hz,1H),3.96–3.91(m,1H),3.11(dd,J=13.7,4.8Hz,1H),3.00(q,J=16.6Hz,2H),2.57(dd,J=13.7,9.1Hz,1H),2.21–2.09(m,1H),2.01(dd,J=17.9,6.5Hz,1H),1.77(m,1H),1.71–1.63(m,1H),1.60(s,3H),1.58–1.50(m,1H),1.50–1.45(m,1H),1.44–1.36(m,2H),1.28–1.11(m,3H),0.95(s,3H),0.89(s,3H),0.84(s,3H).
13 CNMR(101MHz,CDCl 3 )δ167.94,138.23,134.53,129.94,129.38,128.57,126.49,71.52,67.41,51.41,41.72,41.69,38.85,36.60,33.67,33.41,33.29,26.95,21.77,20.24,19.98,19.10,19.04.
Example 3
Figure BDA0004066352810000231
ACID-812 (200 mg,0.8 mmol) was dissolved in dichloromethane (10 mL), 4-dimethylaminopyridine (19 mg,0.16 mmol) and phenylalaninol (181 mg,1.2 mmol) were added, then the above system was transferred to ice bath and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (199mg, 1.0 mmol) was added, stirred at room temperature, monitored by TLC tracking, after completion of the reaction, washed with water, saturated sodium chloride solution respectively, the organic phase was dried over anhydrous sodium sulfate, and the mixture was concentrated. After silica gel column chromatography (eluent: V) Petroleum ether /V Acetic acid ethyl ester =8: 1) AD-12-1 was obtained as a colorless oil in a yield of 74%.
1 HNMR(400MHz,CDCl 3 )δ7.31–7.26(m,2H),7.24–7.18(m,3H),5.94(s,1H),4.73(s,1H),4.47(s,1H),4.19–4.04(m,1H),3.63(m,1H),3.58–3.50(m,1H),3.23(m,1H),2.84(m,2H),2.40–2.31(m,2H),2.28–2.16(m,2H),2.08–1.97(m,1H),1.71(m,1H),1.57–1.44(m,3H),1.41–1.35(m,1H),1.30(dd,J=12.9,4.3Hz,1H),1.15(m,3H),0.87(s,3H),0.79(s,3H),0.65(s,3H).
13 CNMR(101MHz,CDCl 3 )δ173.97,149.25,137.81,129.32,128.72,126.71,106.68,64.30,55.19,53.02,52.53,42.05,39.24,38.97,37.78,36.96,33.67,33.60,32.70,24.13,21.81,19.37,14.64.
AD-12-1 (178 mg,0.46 mmol) was added to a Schlenk tube equipped with a magnetic stirrer, nitrogen was replaced 3 times, methylene chloride was added to dissolve and transfer to-78deg.C, diethylaminosulfur trifluoride (171 μL,1.4 mmol) was slowly added dropwise, the dropwise addition was completed and the reaction was stirred at-78deg.C, TLC was followed by monitoring, after the reaction was completed, the reaction was quenched with water, and thenThe saturated sodium carbonate solution was washed, and the organic phase was dried over anhydrous sodium sulfate, and the mixture was concentrated. After silica gel column chromatography (eluent: V) Petroleum ether /V Acetic acid ethyl ester =9: 1) OZ-12-1 was obtained as colorless oil in 49% yield.
1 HNMR(400MHz,CDCl 3 )δ7.31–7.25(m,2H),7.23–7.16(m,3H),4.80(s,1H),4.64(s,1H),4.31(m,1H),4.09(t,J=8.9Hz,1H),3.89(dd,J=8.4,7.0Hz,1H),3.07(dd,J=13.7,5.1Hz,1H),2.56(dd,J=13.7,8.8Hz,1H),2.49–2.34(m,3H),2.31(dd,J=9.5,4.4Hz,1H),2.11(td,J=13.0,5.3Hz,1H),1.73(m,1H),1.66(m,1H),1.61–1.45(m,2H),1.44–1.36(m,1H),1.32(td,J=12.8,4.3Hz,1H),1.25–1.12(m,3H),0.88(s,3H),0.82(s,3H),0.71(s,3H).
13 CNMR(101MHz,CDCl 3 )δ168.46,148.63,138.31,129.33,128.59,126.49,107.06,71.53,67.41,55.20,53.02,42.17,41.86,39.32,39.04,37.86,33.75,33.66,24.46,24.16,21.87,19.45,14.31.
Example 4
Figure BDA0004066352810000241
ACID-78 (330 mg,1.3 mmol) was dissolved in dichloromethane (15 mL), 4-dimethylaminopyridine (32.0 mg,0.26 mmol) and phenylalaninol (319 mg,1.7 mmol) were added, then the above system was transferred to ice bath and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (329 mg,1.7 mmol) was added, stirred at room temperature, monitored by TLC tracking, after completion of the reaction, the organic phase was washed with water, saturated sodium chloride solution, respectively, dried over anhydrous sodium sulfate, and the mixture was concentrated. After silica gel column chromatography (eluent: V) Petroleum ether /V Acetic acid ethyl ester =2: 1) AD-8-1 was obtained as a colorless oil in a yield of 76%.
1 HNMR(400MHz,CDCl 3 )δ7.33–7.27(m,2H),7.22(m,3H),5.90(d,J=7.4Hz,1H),5.39(s,1H),4.23–4.12(m,1H),3.70–3.54(m,2H),3.22(m,1H),2.91(dd,J=13.8,7.3Hz,1H),2.82(dd,J=13.8,7.4Hz,1H),2.49–2.42(m,1H),2.25(dd,J=15.7,2.8Hz,1H),1.96(m,3H),1.81(m,1H),1.61(m,1H),1.55(s,3H),1.51–1.35(m,3H),1.24(dd,J=12.1,4.7Hz,1H),1.15(td,J=13.0,4.2Hz,1H),1.03(td,J=12.8,4.3Hz,1H),0.86(s,3H),0.85(s,3H),0.69(s,3H).
13 CNMR(101MHz,CDCl 3 )δ174.90,137.71,133.97,129.28,128.79,126.81,122.88,64.47,53.15,50.48,49.81,42.12,39.20,37.07,36.05,34.66,33.28,33.03,23.77,21.97,21.81,18.88,14.28.
AD-8-1 (156 mg,0.4 mmol) was added to a Schlenk tube equipped with a magnetic stirrer, nitrogen was replaced 3 times, methylene chloride was added to dissolve and transfer to-78deg.C, diethylaminosulfur trifluoride (146 μL,1.2 mmol) was slowly added dropwise, the dropwise addition was completed and the reaction was stirred at-78deg.C, followed by monitoring by TLC, after completion of the reaction, the reaction was quenched with water, washed with saturated sodium carbonate solution, the organic phase was dried over anhydrous sodium sulfate, and the mixture was concentrated. After silica gel column chromatography (eluent: V) Petroleum ether /V Acetic acid ethyl ester =9: 1) OZ-8-1 was obtained as colorless oil in 77% yield.
1 HNMR(400MHz,CDCl 3 )δ7.31–7.26(m,2H),7.24–7.17(m,3H),5.42(s,1H),4.41–4.29(m,1H),4.14(dd,J=9.3,8.5Hz,1H),3.94(dd,J=8.5,7.2Hz,1H),3.09(dd,J=13.7,5.0Hz,1H),2.63(dd,J=13.7,8.7Hz,1H),2.45(d,J=9.1Hz,1H),2.35(dt,J=16.2,2.3Hz,1H),2.16(m,1H),2.05–1.92(m,1H),1.89–1.83(m,1H),1.79(m,1H),1.74(s,1H),1.63(s,3H),1.54(dt,J=13.4,3.1Hz,1H),1.51–1.45(m,1H),1.45–1.38(m,1H),1.29(dd,J=12.1,4.8Hz,1H),1.20(dd,J=13.0,3.8Hz,1H),1.12(td,J=13.1,3.9Hz,1H),0.88(s,4H),0.86(s,3H),0.77(s,3H).
13 CNMR(101MHz,CDCl 3 )δ169.51,138.11,134.15,129.40,128.61,126.56,122.89,71.60,67.36,51.30,49.90,42.22,41.61,39.22,36.37,33.34,33.10,26.40,23.84,21.98(2C),18.97,13.81.
Example 5
Figure BDA0004066352810000251
Sclareolide (10.0 g,39.9 mm) was weighedol) in 150mL diethyl ether, 58mL1.6M methyl lithium in 58mL diethyl ether solution, dropwise adding methyl lithium solution into sclareolide diethyl ether solution at-78deg.C, stirring at-78deg.C for 1.5 hr, adding 50mL10% H 2 SO 4 Quenching the aqueous solution, separating the organic phase, extracting with diethyl ether (100 mL×3), washing with sodium bicarbonate aqueous solution, water and saturated sodium chloride aqueous solution, drying with anhydrous sodium sulfate, filtering, and removing the solvent under reduced pressure to obtain the crude methyl ketone product with a yield of 98%, which is directly used in the next reaction.
Methyl ketone (118.0 mg,0.43 mmol) was weighed and dissolved in a mixture of 50% aqueous potassium hydroxide (2 mL) and ethanol (2 mL), 2-aminobenzaldehyde (57.0 mg,0.47 mmol) was added, the reaction mixture was stirred at room temperature for 24 hours, ice water was added to quench the reaction system, the mixture was acidified with dilute acetic acid, extracted with ethyl acetate, and the saturated sodium chloride solution (10 mL. Times.2) was washed, dried over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure, and after silica gel column chromatography (eluent: V) Petroleum ether /V Acetic acid ethyl ester =3: 1) QL was obtained as a white solid in 91% yield.
1 HNMR(500MHz,CDCl 3 )δ8.05(d,J=8.4Hz,1H),7.98(d,J=8.5Hz,1H),7.75(dd,J=8.0,1.4Hz,1H),7.65(m,1.4Hz,1H),7.46(m,1.2Hz,1H),7.31(d,J=8.4Hz,1H),3.17(dd,J=15.5,5.5Hz,1H),2.96(dd,J=15.5,2.7Hz,1H),2.04(dt,J=12.5,3.1Hz,1H),1.91(dd,J=5.5,2.7Hz,1H),1.82–1.77(m,1H),1.69(m,1H),1.64–1.53(m,2H),1.33(m,6H(s,3H)),1.04(td,J=13.5,4.1Hz),0.95–093(m,4H(s,3H)),0.84(s,3H),0.80(s,3H),0.74(td,J=13.2,3.9Hz,1H).
13 CNMR(126MHz,CDCl 3 )δ164.50,147.12,137.00,129.75,128.32,127.52,126.57,125.97,121.85,72.53,61.18,56.22,44.35,41.92,39.76,39.54,34.39,33.44,33.38,24.99,21.53,20.61,18.56,15.83.
Example 6
Synthesis of intermediate AMINE
Figure BDA0004066352810000261
Compound a (2.4. G,9.04mmol,1 equiv.) is weighed into a eggplant-shaped bottle, diethylenetriamine (20 mL,180mmol,20 equiv.) is added, stirred for 12 hours (TLC monitored complete reaction) at 140 ℃, 30mL of water, ethyl acetate and methanol (20 ml×2,10:1, v/v) are slowly added thereto for extraction, the organic phase is washed with saturated sodium chloride, dried over anhydrous sodium sulfate, the solvent is spun dry under reduced pressure, and silica gel column chromatography (200-300 m, etoac/meoh=5:1) is separated to give intermediate AMINE, as a white solid, 1.1g, yield 49%.
Figure BDA0004066352810000262
2-Nitrophenyl Formaldehyde (45 mg,0.3 mmol) and AMINE (79 mg,0.33 mmol) were weighed into a pear-shaped bottle, i-PrOH (1 mL) was added, stirring was carried out at 80℃for 4 hours, tri-n-butylphosphine (225. Mu.L, 0.9 mmol) was added after the reaction system had cooled to room temperature, the reaction system was stirred at 80℃for 16 hours and cooled to room temperature, diluted with ethyl acetate, washed successively with saturated aqueous ammonium chloride (10 mL), saturated aqueous sodium chloride (10 mL), dried over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure, and after silica gel column chromatography (eluent: V) Petroleum ether /V Acetic acid ethyl ester =1: 1) IZ was obtained as a white solid in 82% yield.
1 HNMR(400MHz,CDCl 3 )δ7.96(s,1H),7.64(m,2H),7.28–7.24(m,1H),7.06(m,1H),4.65(dd,J=14.3,4.6Hz,1H),4.44(dd,J=14.3,3.7Hz,1H),4.18(br,1H),2.00–1.92(m,2H),1.84–1.78(m,1H),1.72–1.65(m,1H),1.64–1.56(m,1H),1.56–1.46(m,1H),1.44–1.25(m,7H(s,3H)),1.06(td,J=13.5,4.1Hz,1H),0.95(s,3H),0.93–0.86(m,1H),0.85(s,3H),0.81(s,3H).
13 CNMR(101MHz,CDCl 3 )δ148.55,126.09,123.42,121.95,121.71,120.16,117.30,72.42,62.56,55.83,50.25,44.08,41.64,39.30,39.06,33.45,33.37,24.85,21.54,20.45,18.40,16.06.
Application example
The antibacterial activity of the isolated agricultural pathogenic bacteria is evaluated by adopting a flat plate hypha inhibition growth rate method on the drimane type sesquiterpene heterocyclic compound, and a test strain is selected to activate on a PDA flat plate, wherein the test strain comprises common agricultural pathogenic bacteria such as Sclerotinia sclerotiorum (Sclerotinia sclerotiorum), rhizoctonia solani (Rhizoctonia solani) and Botrytis cinerea (Botrytis cinerea). Preparing the compound into PDA drug-containing plates with serial gradient concentration, preparing a test strain into a bacterial cake with the diameter of 5mm, placing the bacterial cake in the center of a drug-containing culture dish, culturing the bacterial cake at the constant temperature of 25 ℃ until the test strain in a blank control dish grows to be close to the edge of the culture dish, measuring the colony diameter of each drug-containing plate by using a crisscross method, calculating the inhibition rate of the compound on hypha growth, and calculating the inhibition rate on diseases according to the following formula:
Figure BDA0004066352810000271
The results of the antibacterial activity test of the Drimane type sesquiterpene heterocyclic compounds on 3 agricultural fungi are shown in table 2.
TABLE 2 antibacterial Activity of Drimane-type sesquiterpene heterocycles against agricultural pathogens (EC 50 ,μM)
Figure BDA0004066352810000272
Figure BDA0004066352810000281
From Table 1, it can be seen that Drimane-type sesquiterpene heterocycles exhibit moderate to excellent antibacterial activity against test pathogens, wherein OZ-1 exhibits broad-spectrum bactericidal activity against Rhizoctonia solani, sclerotinia sclerotiorum and Botrytis cinerea EC 50 38.20. Mu.M, 27.10. Mu.M and 51.14. Mu.M, respectively. The Drimane oxazoline substituent has a certain influence on the antibacterial activity. Oxazolines of C8-C9 double bond drimane skeleton have better activity on rice sheath blight pathogenic bacteria, and EC of OZ-9-2 and OZ-9-3 50 7.20. Mu.M and 7.25. Mu.M, respectively. The change of the heterocyclic type has a significant effect on the antibacterial activity when the Drimane skeleton is the same, and the C8-OHDrimane skeleton, quinoline QL and 2H-indazole IZ have a significant effect on rice sheath blight pathogenThe activity is obviously improved compared with oxazoline, EC 50 9.89. Mu.M and 8.24. Mu.M, respectively.
The foregoing is merely a preferred embodiment of the present invention and it should be noted that modifications and adaptations to those skilled in the art may be made without departing from the principles of the present invention, which are intended to be comprehended within the scope of the present invention.

Claims (9)

1. A Drimane type sesquiterpene heterocyclic compound, which has a structure shown in a formula I, a formula II or a formula III:
Figure FDA0004066352780000011
in the formula I, the 7-8 dotted line is a double bond or the 8-9 dotted line is a double bond or the 9-12 dotted line is a double bond, and when the 7-8 dotted line is a double bond or the 8-9 dotted line is a double bond or the 9-12 dotted line is a double bond in the formula I, the rest dotted line is a single bond; heterocycles are oxazoline groups;
in the formula II, the hetercycles are oxazoline groups;
in formula III, the hetercycles are oxazoline groups, quinoline groups or 2H indazole groups.
2. The Drimane-type sesquiterpene heterocyclic compound according to claim 1, wherein the oxazoline group is
Figure FDA0004066352780000012
One of the following;
the quinolinyl group is one of quinolinyl, 6-methylquinolinyl, 8-methylquinolinyl, 5-methylquinolinyl, 7-methoxyquinolinyl, 7, 8-dimethoxyquinolinyl, 6-nitroquinolinyl, 7-nitroquinolinyl, 5-chloroquinolinyl, 7-chloroquinolinyl, 6-chloro-2-methylquinolinyl, 5-fluoroquinolinyl, 6, 8-dibromoquinolinyl, 6-bromoquinolinyl, 7-trifluoromethyl quinolinyl and 6-iodoquinolinyl;
the 2H indazole group is one of 2H indazolyl, 5-bromo-2H indazolyl, 6-chloro-2H indazolyl, 4-cyano-2H indazolyl, 5-fluoro-2H indazolyl, 4-chloro-2H indazolyl, 4-trifluoromethyl-2H indazolyl, 4-methoxy-2H indazolyl, 5-methoxy-2H indazolyl, N-dimethyl-2H indazolyl and 4-methyl formate-2H indazolyl.
3. The Drimane-type sesquiterpene heterocyclic compound according to claim 1, wherein in the formula I, the formula II or the formula III, the carbon atom three-dimensional configuration connected with the oxazoline group is R-type or S-type.
4. A process for producing a Drimane-type sesquiterpene heterocycle compound according to any one of claim 1 to 3,
when the Drimane type sesquiterpene heterocyclic compound has a structure shown in a formula I, the method comprises the following steps:
(1) Under the action of diisobutyl aluminum hydride, sclareolide undergoes a reduction reaction to obtain a hemiacetal compound with a structure shown in a formula a;
under the action of boron trifluoride diethyl etherate, the hemiacetal compound with the structure shown in the formula a undergoes hydrolysis reaction to obtain delta with the structure shown in the formula b 8,9 Aldehyde compounds with double bonds at the positions;
under the action of an oxidant, carrying out oxidation reaction on the compound with the structure shown in the formula b to obtain delta with the structure shown in the formula c 8,9 An acid compound having a double bond at the position;
Figure FDA0004066352780000021
(2) Performing ring-opening reaction on sclareolide and N, O-dimethylhydroxylamine hydrochloride to obtain an amide compound with a structure shown in a formula d;
the amide compound with the structure shown in the formula d is subjected to dehydration reaction To obtain delta with the structure shown in formula e 8,12 Amide compounds with double bonds at the positions;
under the action of diisobutylaluminum hydride, delta with the structure shown in formula e 8,12 The reduction reaction of the amide compound with double bond at the position is carried out to obtain delta with the structure shown in the formula f 8,12 Aldehyde compounds with double bonds at the positions;
under the action of oxidant, delta with structure shown as formula f 8,12 The aldehyde compound with double bonds at the position is subjected to oxidation reaction to obtain delta with the structure shown in the formula g 8,12 An acid compound having a double bond at the position;
Figure FDA0004066352780000031
(3) Under the acidic condition, carrying out configuration conversion on sclareolide to obtain C8-S sclareolide with a structure shown in a formula h;
performing ring-opening reaction on C8-S-type sclareolide with a structure shown in formula h and N, O-dimethylhydroxylamine hydrochloride to obtain an amide compound with a structure shown in formula i;
the amide compound with the structure shown in the formula i is dehydrated to obtain delta with the structure shown in the formula j 7,8 Amide compounds with double bonds at the positions;
under the action of lithium aluminum hydride, delta with the structure shown in formula j 7,8 The reduction reaction of the amide compound with double bond at the position is carried out to obtain delta with the structure shown in the formula k 7,8 Aldehyde compounds with double bonds at the positions;
under the action of oxidant, delta with structure shown as formula k 7,8 Oxidizing aldehyde compound with double bond in the position to obtain delta with the structure shown in the formula I 7,8 An acid compound having a double bond at the position;
Figure FDA0004066352780000032
(4) Delta having Structure shown in c 8,9 Acid compound having double bond at position and represented by formula gDelta of structure 8,12 Acid compound having double bond at position or delta having structure represented by formula l 7,8 Performing condensation reaction on the acid compound with the double bond at the position and the chiral amino alcohol compound to obtain an amide alcohol intermediate;
under the action of diethylaminosulfur trifluoride, the amide alcohol intermediate undergoes cyclization reaction to obtain a Drimane type sesquiterpene heterocyclic compound with a structure shown in a formula I;
(II) when the Drimane type sesquiterpene heterocyclic compound has a structure shown in a formula II, the method comprises the following steps:
under the catalysis of ruthenium trichloride, sclareol and an oxidant are subjected to oxidation reaction to obtain an intermediate acid with a structure shown in a formula m;
Figure FDA0004066352780000041
performing condensation reaction on the intermediate acid with the structure shown in the formula m and a chiral amino alcohol compound to obtain an amide alcohol intermediate;
under the action of diethylaminosulfur trifluoride, the amide alcohol intermediate undergoes cyclization reaction to obtain a Drimane type sesquiterpene heterocyclic compound with a structure shown in a formula II;
(III) when the Drimane type sesquiterpene heterocyclic compound has a structure shown in a formula III, the method comprises the following steps:
(i) When the hetercycles are oxazoline groups, comprising the steps of:
under the action of organic alkali, carrying out hydrolysis reaction on the Drimane type sesquiterpene heterocyclic compound with the structure shown in the formula II to obtain the Drimane type sesquiterpene heterocyclic compound with the structure shown in the formula III;
(ii) When the hetercycles are quinolines, the method comprises the steps of:
performing ring-opening reaction on sclareolide and methyl lithium to obtain an intermediate ketone compound with a structure shown in formula n;
Figure FDA0004066352780000042
performing a Friedel-crafts quinoline synthesis reaction on an intermediate ketone compound with a structure shown in a formula n and a 2-aminobenzaldehyde compound to obtain a Drimane type sesquiterpene heterocyclic compound with a structure shown in a formula III;
(iii) When the hetercycles are 2H indazole groups, the method comprises the following steps:
sclareolide and NH under the catalysis of sodium methoxide 3 Carrying out ammonolysis reaction to obtain a compound with a structure shown in a formula o;
under alkaline conditions, carrying out Huffman rearrangement reaction on the compound with the structure shown in the formula o to obtain a compound with the structure shown in the formula p;
Figure FDA0004066352780000051
Under the action of diethylenetriamine, carrying out alkaline hydrolysis reaction on a compound with a structure shown in a formula p to obtain an intermediate amine compound with a structure shown in a formula q;
under the action of tri-n-butyl phosphine, an intermediate amine compound with a structure shown in a formula q and a 2-nitrobenzaldehyde compound undergo a reduction cyclization reaction to obtain a Drimane type sesquiterpene heterocyclic compound with a structure shown in a formula III.
5. The method according to claim 4, wherein in the step (1) in the step (one), the temperature of the reduction reaction is-80 to-60 ℃;
the oxidant is sodium chlorite;
in the step (2) in the step (one), the temperature of the ring-opening reaction is-10-35 ℃;
the catalyst for the dehydration reaction is thionyl chloride and pyridine, and the temperature of the dehydration reaction is-80 to-60 ℃;
the temperature of the reduction reaction is-80 to-60 ℃;
the oxidant is sodium chlorite;
in the step (3) of the step (one), the temperature of the ring-opening reaction is-10-35 ℃;
the catalyst for the dehydration reaction is thionyl chloride and pyridine, and the temperature of the dehydration reaction is-20 ℃;
the temperature of the reduction reaction is-80 to-60 ℃;
The oxidant is sodium chlorite;
in the step (4) of the step (one), the temperature of the condensation reaction is 0-room temperature;
the temperature of the cyclization reaction is-80 to-60 ℃.
6. The method according to claim 4, wherein in the second step, the temperature of the oxidation reaction is 40 ℃;
the temperature of the condensation reaction is 0-room temperature;
the temperature of the cyclization reaction is-80 to-60 ℃.
7. The method according to claim 4, wherein in step (i) of step (III), the hydrolysis reaction temperature is from 0℃to reflux temperature;
in the step (ii) of the step (three), the temperature of the ring-opening reaction is-80 to-60 ℃;
the temperature of the synthesis reaction of the friedel-crafts quinoline is room temperature;
in the step (iii) of the step (III), the temperature of the ammonolysis reaction is 40-80 ℃;
the temperature of the Huffman rearrangement reaction is 0-room temperature;
the temperature of the alkaline hydrolysis reaction is 120-160 ℃;
the reaction temperature of the reductive cyclization is 60-100 ℃.
8. The use of a Drimane-type sesquiterpene heterocyclic compound according to any one of claims 1 to 3 or a Drimane-type sesquiterpene heterocyclic compound prepared by the preparation method according to any one of claims 4 to 7 in resisting agricultural pathogenic bacteria.
9. The use according to claim 8, wherein the agricultural pathogenic bacteria are one or more of sheath blight of rice, sheath blight of wheat, sclerotinia rot of rape, gibberella wheat, take-all of wheat, botrytis cinerea, late blight of potato, phytophthora capsici, early blight of tomato, bakanae disease of rice, dry rot of potato, anthracnose of cucumber and rice blast.
CN202310070493.5A 2023-02-07 2023-02-07 Drimane type sesquiterpene heterocyclic compound and preparation method and application thereof Active CN116178297B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310070493.5A CN116178297B (en) 2023-02-07 2023-02-07 Drimane type sesquiterpene heterocyclic compound and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310070493.5A CN116178297B (en) 2023-02-07 2023-02-07 Drimane type sesquiterpene heterocyclic compound and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN116178297A true CN116178297A (en) 2023-05-30
CN116178297B CN116178297B (en) 2024-05-17

Family

ID=86443741

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310070493.5A Active CN116178297B (en) 2023-02-07 2023-02-07 Drimane type sesquiterpene heterocyclic compound and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN116178297B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106397254A (en) * 2016-08-29 2017-02-15 南京农业大学 Chiral 8-hydroxyhomodrimane sesquiterpene amide compound and application of same as agricultural bactericide
US20190150437A1 (en) * 2016-04-06 2019-05-23 Ohio State Innovation Foundation Use of sesquiterpenes and their analogs as green insecticides for controlling disease vectors and plant pests

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190150437A1 (en) * 2016-04-06 2019-05-23 Ohio State Innovation Foundation Use of sesquiterpenes and their analogs as green insecticides for controlling disease vectors and plant pests
CN106397254A (en) * 2016-08-29 2017-02-15 南京农业大学 Chiral 8-hydroxyhomodrimane sesquiterpene amide compound and application of same as agricultural bactericide

Also Published As

Publication number Publication date
CN116178297B (en) 2024-05-17

Similar Documents

Publication Publication Date Title
CN1099408C (en) Biocidal oximido ether compound
CN112062759B (en) Ethylsulfonyl-containing pyridine-1, 2, 4-oxadiazole substituted benzamide compounds and preparation method and application thereof
JPH02180868A (en) Preparation of 3,5-dimethyl-4-methoxypyridine derivative and novel intermediate therefor
CN112174952B (en) Beta-carboline-oxazoline novel multifunctional ligand beta3Carox, its preparation and application
CN116178297B (en) Drimane type sesquiterpene heterocyclic compound and preparation method and application thereof
CN109705094A (en) A kind of preparation method of pyridine quinazoline
CN109467532B (en) Preparation method of 4-trifluoromethyl nicotinic acid
Reddy et al. An efficient catalyst-free one-pot synthesis of primary amides from the aldehydes of the Baylis–Hillman reaction
CN108148021A (en) 2- imines (3H) furane derivative or thiophene derivant and its synthesis
JPH0784413B2 (en) 3- (Unsubstituted or substituted benzyl) -1-alkyl-2-oxocyclopentanecarboxylic acid alkyl ester derivative, its production method, bactericide and use as intermediate
CN113292487B (en) Preparation method of pyroxsulam intermediate
Brady et al. Halogenated ketenes. 37. The synthesis of pyranones utilizing the (4+ 2) cycloaddition of ketenes and siloxy dienes
CN114213398B (en) Preparation method of polysubstituted furan derivative, bactericide and application
CN113149899A (en) Method for preparing 4-trifluoromethyl nicotinic acid
CN114716344B (en) 2- ((2-acetamidophenyl) amino) acetamido compound and preparation method and application thereof
US6072074A (en) Process for producing 3-propynyl-2-2-dimethylcycloprophane-carboxylic acid and its lower akyl esters
CN115918662B (en) Application of 3-aryl isoquinoline berberine simplified derivative in preventing and treating agricultural disease fungi
CN114716451B (en) Frutinone compound and preparation method and application thereof
CN115160159B (en) Halichonin B analogue, preparation method thereof and application thereof in preparing agricultural bactericide
WATANABE et al. Chemistry of Diborane and Sodium Borohydride. VIII. Imidate Formation from Nitriles with Sodium Borohydride
CN115433141B (en) Alpha-oximino phenylacetamide compound, preparation method thereof and application thereof as agricultural bactericide
JP3981771B2 (en) 2-Benzyloxy-6-alkoxybenzoic acid derivative, method for producing the same, and agricultural and horticultural fungicide
KR102087160B1 (en) Pyridine n-oxides and processes for their preparation
CN108164435B (en) Green and efficient synthesis method of aryl acrylonitrile compound
CN111533667B (en) Synthetic method of 2,2-dimethyl-4-phenylpent-4-enenitrile compound

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant